Mikael Dolsten M.D., Ph.D. — President of Worldwide Research & Development and Executive VP at Pfizer

Dr. Mikael Dolsten, MD, Ph.D., has been the President of Worldwide Research and Development at Pfizer Inc. since December 2010 and has been its Executive VP since June 13, 2017. Dr. Dolsten serves as an Executive Vice President of Pfizer Inc. Dr. Dolsten also serves as a Member of Pfizer Executive Leadership Team. Dr. Dolsten serves as the President of Worldwide Research and Development at Pfizer Limited. Prior to joining Pfizer in 2009, he served as Senior Vice President of Wyeth and President of Wyeth Research, where he was responsible for the global R&D division and led scientists across the US, Europe and Asia. Before joining Wyeth, he served as an Executive Vice President at Boehringer Ingelheim, where he was responsible for worldwide research including activities at R&D sites in the US, Canada, Germany, Italy, Austria and Japan. He served as Head of Corporate Division Pharma Research/Discovery at Boehringer Ingelheim with responsible for approximately 1400 discovery scientists and world-wide research in respiratory, immunology/inflammation, metabolic disease, CNS/pain, oncology and cardiovascular therapies. Dr. Dolsten was a Partner at OrbiMed Advisors, L.L.C. He held various senior R&D management positions including: Head of Preclinical Research Oncology/Immunology at Pharmacia & Upjohn, Lund and Head of Preclinical R&D, Vice President of Respiratory and Inflammation at Astra Draco, Lund. In addition, he gained leadership experience from five large-scale M&A transactions. He served as the President of BioTherapeutics Research & Development at Pfizer Inc. from October 2009 to May 2010 and served as its Senior Vice President from May 2010 to December 2010. Prior to joining Boehringer Ingelheim in 2003, Dr. Dolsten was responsible for integrating several areas of AstraZeneca Discovery post-merger. He also served as Global Vice President/Head of Cardiovascular/Metabolic & Gastrointestinal Discovery at AstraZeneca. Dr. Dolsten has spent approximately seventeen years in the pharmaceutical Industry. He has been Chairman, Translational Advisory Board of Apple Tree Partners since 2016. Dr. Dolsten has been an Independent Director at Karyopharm Therapeutics Inc. since March 31, 2015. He serves as a Member of Translational Advisory Board at Apple Tree Partners. He serves as a Member of MDL Scientific Advisory Board at Elsevier B.V. He served as a Director of Receptos, Inc. He is a Member of the Biomedical Advisory Council of The Pharmaceutical Research and Manufacturers of America (PhRMA) and serves on the PhRMA Foundation Board of Directors. He has been a Board Member of a Swedish Business School for Innovation and Chamber of Commerce. He is a Governor of the New York Academy of Sciences. He was appointed as Adjunct Professor in Immunology at the Medical Faculty in Lund, Sweden. He was Associate Professor at Lund University since 1989 and Adjunct Professor in Cell and Molecular Biology since 1996. Dr. Dolsten is a named inventor on several patents and has published approximately 150 articles in international journals, with particular contributions in areas such as molecular cell biology, immunology and oncology. He earned his Ph.D. in Tumor Immunology and M.D. from the University of Lund in Sweden. He also studied Virology and Cell Biology at the Weizmann Institute in Israel.